![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Japan Approves Opdivo for Unresectable Advanced or Recurrent Esophageal Cancer
Japan Approves Opdivo for Unresectable Advanced or Recurrent Esophageal Cancer
Japan’s Ministry of Health, Labor, and Welfare approved Bristol-Myers Squibb’s Opdivo (nivolumab) for patients with unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy.
The approval was supported by the results of a phase 3 clinical trial in which Opdivo demonstrated a 23 percent reduction in the risk of death and a 2.5-month improvement in median overall survival compared with chemotherapy.
Opdivo is currently approved in more than 65 countries, including thirteen approved indications in the U.S.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct